A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01368926
Recruitment Status : Completed
First Posted : June 8, 2011
Last Update Posted : November 2, 2016
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This double-blind, randomized, placebo-controlled, 2-Part study will evaluate the pharmacokinetics and safety of RO4917523 in healthy Japanese and Caucasian volunteers. In Part 1, healthy Japanese volunteers will be randomized to receive 2 oral doses of either RO4917523 or placebo, with a washout period of 21 days between dosing. In Part 2, healthy Japanese and Caucasian volunteers will be randomized in cohorts to receive either RO4917523 or placebo orally daily for 14 days.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: RO4917523 Drug: placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics, Safety and Tolerability of RO4917523 Conducted in 2 Phases: a Single-Dose, Cross-Over Administration to Healthy Japanese Subjects and a Multiple-Dose Administration to Healthy Japanese and Caucasian Subjects.
Study Start Date : June 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Arm Intervention/treatment
Experimental: Part 1 Drug: RO4917523
single oral doses

Drug: placebo
oral doses

Experimental: Part 2 Drug: RO4917523
multiple oral doses

Drug: placebo
oral doses

Primary Outcome Measures :
  1. Part 1: Pharmacokinetics: Area under the concentration - time curve (AUC) (single/multiple oral dose in healthy Japanese subjects) [ Time Frame: approximately 12 weeks ]
  2. Part 2: Comparison of pharmacokinetics (area under the concentration - time curve [AUC]) between healthy Caucasian and Japanese subjects after 14 days of daily oral dosing [ Time Frame: approximately 9 weeks ]
  3. Safety: Incidence of adverse events in Japanese an Caucasian subjects [ Time Frame: approximately 21 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy Japanese (Part 1 + 2) or Caucasian (Part 2) adults, 18- 50 years of age
  • Japanese subjects must have Japanese parents and grandparents who were born in Japan
  • Caucasian subjects must have 4 Caucasian grandparents
  • Body mass index (BMI) 18.5 to 26 kg/m2, and a body weight of at least 45 kg
  • Non-smoker for at least 90 days prior to dosing Day 1

Exclusion Criteria:

  • Participation in a clinical trial with an investigational drug within 90 days prior to dosing Day 1. (Volunteers having participated in Part 1 will not be allowed to participate in Part 2 and vice versa)
  • History or evidence of any clinically significant disease or disorder
  • Pregnant or lactating women
  • Positive for hepatitis B, hepatitis C or HIV
  • Positive drug screen test, positive cotinine test and/or positive alcohol test
  • Any confirmed significant allergic reactions to any drug, or multiple allergies in the judgement of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01368926

United States, New York
New York, New York, United States, 10016
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche

Responsible Party: Hoffmann-La Roche Identifier: NCT01368926     History of Changes
Other Study ID Numbers: BP25713
First Posted: June 8, 2011    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: November 2016